A growing body of evidence reveals a critical oversight in heart failure management: one-third of hospitalized heart failure patients suffer from thiamine deficiency, compared with just 12% of matched controls. The culprit is often the very medication designed to relieve their symptoms—loop diuretics, which accelerate urinary thiamine loss and deplete the body’s modest stores within weeks.
Thiamine pyrophosphate serves as the essential cofactor for pyruvate dehydrogenase, the primary enzymatic gateway for converting glucose into ATP within cardiac mitochondria. Without adequate thiamine, pyruvate cannot enter the mitochondria, lactate accumulates, and cardiac energy production falters—a metabolic cascade with potentially serious clinical consequences.
Despite this clear mechanistic link and measurable deficiency rates, routine thiamine screening remains rare in clinical practice. This gap between evidence and implementation deserves urgent attention from clinicians managing heart failure populations.
Was this article helpful?
